Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.70 |
| ▸ | DRD3 | P35462 | 11/20 | 0.70 |
| ▸ | HTR1A | P08908 | 5/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483129 | 0.82 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4SIGMAR1 | |
| SCHEMBL6352686 | 0.74 | HTR1A (1.00) | DRD2DRD3HTR1A | |
| SCHEMBL7344010 | 0.74 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| Fumaric Acid SCHEMBL2965270 | 0.73 | DRD2 (0.79) | DRD2DRD3HTR1A | |
| SCHEMBL7376178 | 0.72 | DRD2 (0.62) | DRD2DRD3HTR1A | |
| SCHEMBL3222580 | 0.71 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4 | |
| SCHEMBL7343813 | 0.71 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL7343645 | 0.71 | DRD2 (0.61) | DRD2DRD3HTR1A | |
| SCHEMBL1792787 | 0.69 | GRIN2B (0.61) | DRD2DRD3HTR1ADRD4SIGMAR1 | |
| SCHEMBL7348495 | 0.68 | DRD2 (0.58) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| WO-2005051488-A1 | COMBINATION OF DOPAMINE AGONISTS AND MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | claimed |
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005051488-A1 | COMBINATION OF DOPAMINE AGONISTS AND MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | HTR5A, SLC6A3, SLC6A4 | DRD2 37/4885DRD3 118/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.